What is China Sxt Pharmaceuticals Inc's earnings per share (EPS)?

China Sxt Pharmaceuticals Inc (SXTC) reported diluted earnings per share of $-9.13 for fiscal year 2026. This represents a 97.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

China Sxt Pharmaceuticals Inc Financials

SXTC

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE March

This page shows China Sxt Pharmaceuticals Inc (SXTC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SXTC FY2025 2026-07-01

A cash-heavy, low-debt balance sheet is being maintained by external financing rather than by the operating business.

From FY2024 to FY2025, cash and equivalents rose from $12.1M to $18.1M while total liabilities fell from $9.2M to $6.2M, even though cumulative operating cash flow over those two years was -$4.3M. That cleaner balance sheet was created by financing activity, especially FY2025 financing inflow of $8.4M, not by the core business turning cash-generative.

In FY2025, gross profit of $367K covered only a small slice of SG&A at $2.8M, which means losses are mainly a scale problem: the sales base is too small to carry overhead. Interest expense was only $106K, so debt reduction by itself would not solve profitability.

Liquidity looks much stronger than the income statement: cash represented about 83.5% of total assets in FY2025, and the current ratio improved to 3.5x from 1.6x in FY2024. But with net margin at -189.8% and operating cash flow at -$2.3M, that cash pile currently functions more like runway than proof that earnings are converting into cash.

Financial Health Signals

Financial Health Score 35/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of China Sxt Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Safe

10.51

China Sxt Pharmaceuticals Inc scores 10.51, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($96.7M) relative to total liabilities ($5.0M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

China Sxt Pharmaceuticals Inc passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.65x

For every $1 of reported earnings, China Sxt Pharmaceuticals Inc generates $0.65 in operating cash flow (-$4.0M OCF vs -$6.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-113.1x

China Sxt Pharmaceuticals Inc earns $-113.1 in operating income for every $1 of interest expense (-$7.1M vs $63K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.1M

YoY-34.6%

5Y CAGR-24.9%

China Sxt Pharmaceuticals Inc generated $1.1M in revenue in fiscal year 2026. This represents a decrease of 34.6% from the prior year.

EBITDA

-$7.0M

YoY-171.3%

China Sxt Pharmaceuticals Inc's EBITDA was -$7.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 171.3% from the prior year.

Net Income

-$6.2M

YoY-87.8%

China Sxt Pharmaceuticals Inc reported -$6.2M in net income in fiscal year 2026. This represents a decrease of 87.8% from the prior year.

EPS (Diluted)

$-9.13

YoY+97.4%

China Sxt Pharmaceuticals Inc earned $-9.13 per diluted share (EPS) in fiscal year 2026. This represents an increase of 97.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$4.0M

YoY-71.2%

China Sxt Pharmaceuticals Inc generated -$4.0M in free cash flow in fiscal year 2026, representing cash available after capex. This represents a decrease of 71.2% from the prior year.

Cash & Debt

$28.2M

YoY+55.7%

5Y CAGR+16.1%

China Sxt Pharmaceuticals Inc held $28.2M in cash against $644K in long-term debt as of fiscal year 2026.

Dividends Per Share

N/A

Shares Outstanding

958,077

China Sxt Pharmaceuticals Inc had 958,077 shares outstanding in fiscal year 2026.

Margins & Returns

Gross Margin

21.9%

YoY+0.7pp

5Y CAGR-37.6pp

China Sxt Pharmaceuticals Inc's gross margin was 21.9% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is up 0.7 percentage points from the prior year.

Operating Margin

-625.9%

YoY-471.9pp

5Y CAGR-579.9pp

China Sxt Pharmaceuticals Inc's operating margin was -625.9% in fiscal year 2026, reflecting core business profitability. This is down 471.9 percentage points from the prior year.

Net Margin

-545.2%

YoY-355.5pp

5Y CAGR-487.7pp

China Sxt Pharmaceuticals Inc's net profit margin was -545.2% in fiscal year 2026, showing the share of revenue converted to profit. This is down 355.5 percentage points from the prior year.

Return on Equity

-20.9%

YoY+0.5pp

5Y CAGR-3.7pp

China Sxt Pharmaceuticals Inc's ROE was -20.9% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is up 0.5 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$2K

YoY+0.0%

China Sxt Pharmaceuticals Inc invested $2K in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents an increase of 0.0% from the prior year.

SXTC Income Statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21
Revenue	$1.1M-34.6%	$1.7M-9.7%	$1.9M-2.2%	$2.0M-24.2%	$2.6M-45.5%	$4.8M
Cost of Revenue	$889K-35.2%	$1.4M-0.1%	$1.4M-11.1%	$1.5M+14.4%	$1.4M-30.3%	$1.9M
Gross Profit	$249K-32.3%	$367K-33.7%	$554K+30.0%	$426K-65.9%	$1.3M-55.9%	$2.8M
R&D Expenses	N/A	N/A	$184K-8.2%	$201K-45.3%	$367K	N/A
SG&A Expenses	$7.1M+158.4%	$2.8M+4.6%	$2.6M-53.3%	$5.6M+2.3%	$5.5M+59.9%	$3.4M
Operating Income	-$7.1M-165.7%	-$2.7M-6.6%	-$2.5M+55.1%	-$5.6M-8.1%	-$5.2M-136.2%	-$2.2M
Interest Expense	$63K-40.7%	$106K-54.1%	$232K-51.4%	$477K+1199.3%	$37K-97.7%	$1.6M
Income Tax	N/A	N/A	N/A	N/A	$328K+270.3%	-$193K
Net Income	-$6.2M-87.8%	-$3.3M-6.6%	-$3.1M+47.8%	-$5.9M-3.5%	-$5.7M-108.7%	-$2.7M
EPS (Diluted)	$-9.13+97.4%	$-348.17+91.9%	$-4285.66-2309.9%	$-177.84	$-137.92-3511.4%	$-3.82

Metric	Q4'26	Q2'26	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SXTC Balance Sheet

Metric	FY26	FY25	FY24	FY23	FY22	FY21
Total Assets	$34.8M+60.4%	$21.7M-6.3%	$23.1M-21.7%	$29.6M-11.9%	$33.5M-2.9%	$34.5M
Current Assets	$34.5M+62.0%	$21.3M+49.6%	$14.2M-27.1%	$19.5M-13.1%	$22.5M-3.4%	$23.2M
Cash & Equivalents	$28.2M+55.7%	$18.1M+49.9%	$12.1M-30.5%	$17.4M+11.9%	$15.5M+16.4%	$13.3M
Inventory	$777K-6.2%	$828K+4.2%	$795K+49.6%	$531K-47.8%	$1.0M+18.4%	$860K
Accounts Receivable	$932K-28.4%	$1.3M-1.0%	$1.3M-2.2%	$1.3M-59.7%	$3.3M-26.0%	$4.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.0M-18.9%	$6.2M-32.3%	$9.2M-38.1%	$14.9M-13.2%	$17.1M-7.9%	$18.6M
Current Liabilities	$4.3M-27.7%	$6.0M-32.5%	$8.9M-38.6%	$14.5M-15.3%	$17.1M-7.8%	$18.6M
Long-Term Debt	$644K+569.4%	$96K-17.8%	$117K-0.6%	$118K	N/A	$6K
Total Equity	$29.7M+92.4%	$15.4M+10.8%	$13.9M-5.2%	$14.7M-8.7%	$16.1M+0.8%	$16.0M
Retained Earnings	-$34.2M-22.1%	-$28.0M-13.4%	-$24.7M-14.3%	-$21.6M-37.8%	-$15.7M-57.6%	-$10.0M

Metric	Q4'26	Q2'26	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23
Total Assets	$34.8M+31.9%	$26.4M+21.6%	$21.7M-30.1%	$31.0M+34.0%	$23.1M+58.5%	$14.6M-50.6%	$29.6M+33.2%	$22.2M
Current Assets	$34.5M+32.5%	$26.0M+22.3%	$21.3M-3.1%	$22.0M+54.5%	$14.2M+5.5%	$13.5M-30.9%	$19.5M+57.9%	$12.4M
Cash & Equivalents	$28.2M+33.1%	$21.2M+16.9%	$18.1M-2.2%	$18.5M+53.4%	$12.1M+5.3%	$11.5M-34.0%	$17.4M+482.6%	$3.0M
Inventory	$777K+3.4%	$751K-9.3%	$828K-4.5%	$867K+9.1%	$795K+61.2%	$493K-7.2%	$531K-15.4%	$628K
Accounts Receivable	$932K-30.3%	$1.3M+2.7%	$1.3M-21.8%	$1.7M+26.6%	$1.3M+0.3%	$1.3M-2.5%	$1.3M-59.5%	$3.3M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.0M-17.5%	$6.1M-1.7%	$6.2M-61.0%	$16.0M+73.6%	$9.2M-3.3%	$9.5M-36.0%	$14.9M+103.8%	$7.3M
Current Liabilities	$4.3M-27.0%	$6.0M-0.8%	$6.0M-61.6%	$15.7M+76.0%	$8.9M-3.2%	$9.2M-36.5%	$14.5M+98.8%	$7.3M
Long-Term Debt	$644K+781.5%	$73K-24.1%	$96K-16.5%	$115K-1.5%	$117K+9.9%	$107K-9.6%	$118K	N/A
Total Equity	$29.7M+46.8%	$20.2M+31.0%	$15.4M+2.7%	$15.0M+7.9%	$13.9M+174.4%	$5.1M-65.4%	$14.7M+1.0%	$14.5M
Retained Earnings	-$34.2M+0.5%	-$34.4M-22.7%	-$28.0M-9.8%	-$25.5M-3.2%	-$24.7M+21.1%	-$31.3M-44.9%	-$21.6M-25.8%	-$17.2M

SXTC Cash Flow Statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21
Operating Cash Flow	-$4.0M-71.3%	-$2.3M-21.6%	-$1.9M-2287.5%	-$81K-130.1%	$268K+120.4%	-$1.3M
Capital Expenditures	$2K0.0%	$2K-71.4%	$7K	N/A	N/A	N/A
Free Cash Flow	-$4.0M-71.2%	-$2.3M-21.3%	-$1.9M	N/A	N/A	N/A
Investing Cash Flow	-$1.3M-2069.5%	$64K+140.4%	$26K+314.8%	-$12K+73.8%	-$47K+99.2%	-$5.8M
Financing Cash Flow	$14.4M+71.8%	$8.4M+420.0%	-$2.6M-189.2%	$2.9M+84.4%	$1.6M-87.1%	$12.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'26	Q2'26	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SXTC Financial Ratios

Metric	FY26	FY25	FY24	FY23	FY22	FY21
Gross Margin	21.9%+0.7pp	21.1%-7.6pp	28.7%+7.1pp	21.6%-26.5pp	48.1%-11.3pp	59.4%
Operating Margin	-625.9%-471.9pp	-154.0%-23.6pp	-130.4%+154.0pp	-284.4%-85.0pp	-199.4%-153.4pp	-46.0%
Net Margin	-545.2%-355.5pp	-189.8%-29.1pp	-160.7%+140.3pp	-301.0%-80.6pp	-220.4%-162.9pp	-57.5%
Return on Equity	-20.9%+0.5pp	-21.4%+0.8pp	-22.2%+18.2pp	-40.4%-4.7pp	-35.7%-18.5pp	-17.2%
Return on Assets	-17.8%-2.6pp	-15.3%-1.8pp	-13.4%+6.7pp	-20.1%-3.0pp	-17.1%-9.2pp	-8.0%
Current Ratio	7.93+4.4	3.54+1.9	1.60+0.3	1.35+0.0	1.31+0.1	1.25
Debt-to-Equity	0.02+0.0	0.010.0	0.010.0	0.01-1.1	1.06+1.1	0.00
FCF Margin	-353.2%-218.3pp	-134.8%-34.5pp	-100.3%	N/A	N/A	N/A

Metric	Q4'26	Q2'26	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	7.93+3.6	4.37+0.8	3.54+2.1	1.40-0.2	1.60+0.1	1.47+0.1	1.35-0.3	1.70
Debt-to-Equity	0.02+0.0	0.000.0	0.010.0	0.010.0	0.01-0.0	0.02+0.0	0.01-0.5	0.50
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Ironwood IRWD

$768.7M

Journey Medical Corp DERM

$192.7M

Organigram Global Inc OGI

$138.1M

Alpha Teknova TKNO

$290.6M

BioAge Labs Inc. BIOA

$1.1B

Frequently Asked Questions

What is China Sxt Pharmaceuticals Inc's annual revenue?

China Sxt Pharmaceuticals Inc (SXTC) reported $1.1M in total revenue for fiscal year 2026. This represents a -34.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is China Sxt Pharmaceuticals Inc's revenue growing?

China Sxt Pharmaceuticals Inc (SXTC) revenue declined by 34.6% year-over-year, from $1.7M to $1.1M in fiscal year 2026.

Is China Sxt Pharmaceuticals Inc profitable?

No, China Sxt Pharmaceuticals Inc (SXTC) reported a net income of -$6.2M in fiscal year 2026, with a net profit margin of -545.2%.

What is China Sxt Pharmaceuticals Inc's EBITDA?

China Sxt Pharmaceuticals Inc (SXTC) had EBITDA of -$7.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does China Sxt Pharmaceuticals Inc have?

As of fiscal year 2026, China Sxt Pharmaceuticals Inc (SXTC) had $28.2M in cash and equivalents against $644K in long-term debt.

What is China Sxt Pharmaceuticals Inc's gross margin?

China Sxt Pharmaceuticals Inc (SXTC) had a gross margin of 21.9% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is China Sxt Pharmaceuticals Inc's operating margin?

China Sxt Pharmaceuticals Inc (SXTC) had an operating margin of -625.9% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is China Sxt Pharmaceuticals Inc's net profit margin?

China Sxt Pharmaceuticals Inc (SXTC) had a net profit margin of -545.2% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is China Sxt Pharmaceuticals Inc's return on equity (ROE)?

China Sxt Pharmaceuticals Inc (SXTC) has a return on equity of -20.9% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is China Sxt Pharmaceuticals Inc's free cash flow?

China Sxt Pharmaceuticals Inc (SXTC) generated -$4.0M in free cash flow during fiscal year 2026. This represents a -71.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is China Sxt Pharmaceuticals Inc's operating cash flow?

China Sxt Pharmaceuticals Inc (SXTC) generated -$4.0M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are China Sxt Pharmaceuticals Inc's total assets?

China Sxt Pharmaceuticals Inc (SXTC) had $34.8M in total assets as of fiscal year 2026, including both current and long-term assets.

What are China Sxt Pharmaceuticals Inc's capital expenditures?

China Sxt Pharmaceuticals Inc (SXTC) invested $2K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How many shares does China Sxt Pharmaceuticals Inc have outstanding?

China Sxt Pharmaceuticals Inc (SXTC) had 958,077 shares outstanding as of fiscal year 2026.

What is China Sxt Pharmaceuticals Inc's current ratio?

China Sxt Pharmaceuticals Inc (SXTC) had a current ratio of 7.93 as of fiscal year 2026, which is generally considered healthy.

What is China Sxt Pharmaceuticals Inc's debt-to-equity ratio?

China Sxt Pharmaceuticals Inc (SXTC) had a debt-to-equity ratio of 0.02 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is China Sxt Pharmaceuticals Inc's return on assets (ROA)?

China Sxt Pharmaceuticals Inc (SXTC) had a return on assets of -17.8% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is China Sxt Pharmaceuticals Inc's cash runway?

Based on fiscal year 2026 data, China Sxt Pharmaceuticals Inc (SXTC) had $28.2M in cash against an annual operating cash burn of $4.0M. This gives an estimated cash runway of approximately 84 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is China Sxt Pharmaceuticals Inc's Altman Z-Score?

China Sxt Pharmaceuticals Inc (SXTC) has an Altman Z-Score of 10.51, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is China Sxt Pharmaceuticals Inc's Piotroski F-Score?

China Sxt Pharmaceuticals Inc (SXTC) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are China Sxt Pharmaceuticals Inc's earnings high quality?

China Sxt Pharmaceuticals Inc (SXTC) has an earnings quality ratio of 0.65x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can China Sxt Pharmaceuticals Inc cover its interest payments?

China Sxt Pharmaceuticals Inc (SXTC) has an interest coverage ratio of -113.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is China Sxt Pharmaceuticals Inc?

China Sxt Pharmaceuticals Inc (SXTC) scores 35 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.